For the quarter ended June 2025, DexCom (DXCM) reported revenue of $1.16 billion, up 15.2% over the same period last year. EPS came in at $0.48, compared to $0.43 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.12 billion, representing a surprise of +3.06%. The company delivered an EPS surprise of +6.67%, with the consensus EPS estimate being $0.45.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how DexCom performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- United States: $841 million versus the six-analyst average estimate of $809.7 million. The reported number represents a year-over-year change of +14.9%.
- Revenue- International: $316.1 million versus the six-analyst average estimate of $311.29 million. The reported number represents a year-over-year change of +16%.
- Revenue- Hardware: $39.3 million versus the three-analyst average estimate of $38.99 million. The reported number represents a year-over-year change of -31.4%.
- Revenue- Sensor and other: $1.12 billion versus $1.08 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +18% change.
View all Key Company Metrics for DexCom here>>>
Shares of DexCom have returned +6.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DexCom, Inc. (DXCM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
